Ascendis Pharma A (ASND) Receivables - Net (2012 - 2026)

As of Dec 31, 2025, Ascendis Pharma A's Receivables - Net came in at $159.68 million, down 11.3% from the prior year.

• Annual Receivables - Net shows a five-year compound annual growth rate of 222.0% (years ended Dec 2020 to Dec 2025).
• In prior years, Ascendis Pharma A's Receivables - Net was $179.97 million in the year ended Dec 31, 2024 (+363.8%), $38.81 million in the year ended Dec 31, 2023 (+209.1%), $12.55 million in the year ended Dec 31, 2022 (+398.8%) and $2.52 million in the year ended Dec 31, 2021 (+445.4%).
• The figure for the quarter ended Jun 30, 2026 stands as the highest quarterly Receivables - Net in data going back to the quarter ended Dec 31, 2012.
• On a year-over-year basis, Receivables - Net increased in seven of the last eight quarters, with growth averaging 149.3%.
• The strongest year-over-year quarter for Receivables - Net in the past five years was the quarter ended Sep 30, 2022, with growth of 967.5%; the weakest was the quarter ended Sep 30, 2021, with a decline of 80.2%.
• According to Business Quant data, Receivables - Net for the three prior quarters was $209.18 million (quarter ended Mar 31, 2026), $164.52 million (quarter ended Dec 31, 2025) and $157.51 million (quarter ended Sep 30, 2025).